%0 Journal Article %A MOTOYUKI SUZUKI %A YUKINORI TAKENAKA %A TOSHIHIRO KISHIKAWA %A YOSHIFUMI YAMAMOTO %A ATSUSHI HANAMOTO %A YOICHIRO TOMIYAMA %A TAKAHITO FUKUSUMI %A TAKAHIRO MICHIBA %A NORIHIKO TAKEMOTO %A SUSUMU NAKAHARA %A HIDENORI INOHARA %T Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer %D 2021 %R 10.21873/anticanres.14973 %J Anticancer Research %P 2045-2051 %V 41 %N 4 %X Background/Aim: To retrospectively evaluate the efficacy and safety of modified TPEx (docetaxel 60 mg/m2 on day 1, cisplatin 60 mg/m2 on day 1, and weekly cetuximab 250 mg/m2 with loading dose of 400 mg/m2) followed by maintenance cetuximab as first-line treatment for inoperable recurrent and/or metastatic squamous cell carcinoma of the head and neck. Patients and Methods: We analyzed 22 Japanese patients receiving modified TPEx every 21 days for four cycles with or without prophylactic granulocyte colony-stimulating factor (G-CSF). Results: The best overall response rate was 55% [95% confidence interval (CI)=35-73]. The median progression-free survival and overall survival were 8.9 months (95%CI=3.9-10.2) and 14.3 months (95%CI=10.1-28.2), respectively. Without prophylactic G-CSF, Grade 3/4 neutropenia and febrile neutropenia was common (94% versus 20%; p=0.003 and 41% versus 0%; p=0.11, respectively). Conclusion: The modified TPEx is effective, while prophylactic G-CSF is essential. %U https://ar.iiarjournals.org/content/anticanres/41/4/2045.full.pdf